Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.
Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.
These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
調査の概要
詳細な説明
ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).
The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.
Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.
Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.
The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.
Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.
Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Ilya Tsimafeyeu
- 電話番号:+74999054690
- メール:bucare@bucare.org
研究場所
-
-
-
Chelyabinsk、ロシア
- 募集
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
-
コンタクト:
- Natalia Glushankova
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Krasnoyarsk、ロシア
- 募集
- V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
-
コンタクト:
- Ruslan Zukov
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Orenburg、ロシア
- 募集
- Orenburg Regional Cancer Center
-
コンタクト:
- Makhabbat Murzalina
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Saint Petersburg、ロシア
- 募集
- Dr. Berezin Medical Institute
-
コンタクト:
- Grigory Raskin
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Saint Petersburg、ロシア
- 募集
- SBHI Leningrad regional clinical hospital, Saint-Petersburg
-
コンタクト:
- Andrei Lebedinets
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Saratov、ロシア
- 募集
- Saratov Regional Cancer Center
-
コンタクト:
- Svetlana Averianova
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Ufa、ロシア
- 募集
- Republican Clinical Oncology Dispensary
-
コンタクト:
- Alexander Sultanbaev
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
Yekaterinburg、ロシア
- 募集
- Sverdlovskiy Regional Oncological Dispensary
-
コンタクト:
- Marina Zafirova
- 電話番号:+74999054690
- メール:sten_to@mail.ru
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically confirmed chromophobe renal cell carcinoma.
- Measurable disease according to RECIST version 1.1.
- ECOG performance status of 0-3.
- Cohort A: No prior systemic therapy for metastatic disease.
- Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
- Adequate bone marrow, hepatic, and renal function.
- Signed informed consent.
Exclusion Criteria:
- Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
- Uncontrolled hypertension despite appropriate antihypertensive treatment.
- Clinically significant uncontrolled cardiovascular disease.
- Active infection requiring systemic treatment.
- Active clinically significant bleeding or a high risk of severe hemorrhage.
- Major surgery without adequate postoperative recovery or a serious non-healing wound.
- Gastrointestinal conditions that significantly impair the absorption of oral study medications.
- Known severe hypersensitivity to any component of the assigned study treatment.
- Current pneumonitis or interstitial lung disease.
- Pregnancy or breastfeeding.
- Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
- Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort A: first-line lenvatinib plus pembrolizumab
lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks |
tablets solution |
|
実験的:Cohort B: later-line lenvatinib plus everolimus
lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily |
tablets tablets |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate
時間枠:12 months
|
the proportion of patients achieving a complete or partial response according to RECIST version 1.1 |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
progression-free survival
時間枠:24 months
|
the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
24 months
|
|
overall survival
時間枠:24 months
|
the time from treatment initiation to death from any cause |
24 months
|
|
duration of response
時間枠:24 months
|
the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first |
24 months
|
|
Grade 3 and higher treatment-emergent adverse events
時間枠:24 months
|
the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0. |
24 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- ChromoKey
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Study results are disseminated through scientific publications and conference presentations in aggregate form.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。